- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02798679
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity
October 15, 2022 updated by: University of Minnesota
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Consecutive participants with breast cancer or lymphoma scheduled to receive anthracycline-based chemotherapy or trastuzumab.
Description
Inclusion Criteria:
- Stage I-III breast cancer or lymphoma with a >2 year life expectancy
- A treatment plan that includes anthracyclines and/or trastuzumab
- Age >45 years
- Able to hold breath for 10 seconds
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Exclusion Criteria:
- Refusal or inability to provide informed consent
- Known heart failure or LVEF <50%
- Heart rate over 100 bpm
- Renal dysfunction with GFR <30 mL/min/1.73m2
- Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices
- Symptomatic claustrophobia
- Plans to move within 24 months of enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiotoxicity assessed clinically or by cardiac MRI
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chetan Shenoy, MBBS, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Actual)
September 1, 2022
Study Completion (Actual)
September 1, 2022
Study Registration Dates
First Submitted
May 12, 2016
First Submitted That Met QC Criteria
June 8, 2016
First Posted (Estimate)
June 14, 2016
Study Record Updates
Last Update Posted (Actual)
October 18, 2022
Last Update Submitted That Met QC Criteria
October 15, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV-2016-24434
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiotoxicity
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); London Health Sciences Centre; Children's Hospital of Eastern Ontario and other collaboratorsCompletedAnthracycline-induced CardiotoxicityUnited States, Canada
-
West China Second University HospitalRecruitingImmune Checkpoint Inhibitors, CardiotoxicityChina
-
McGill University Health Centre/Research Institute...UnknownChemotherapy, Cancer, Cardiotoxicity, PhysioflowCanada
-
Queen's University, BelfastActive, not recruitingAnthracycline Induced CardiotoxicityUnited Kingdom
-
TC Erciyes UniversityCompletedAnthracycline Induced CardiotoxicityTurkey
-
Yonsei UniversityRecruitingChemotherapy Induced CardiotoxicityKorea, Republic of
-
Texas Tech University Health Sciences CenterRecruitingAnthracycline Related Cardiotoxicity in Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedChemotherapy Induced Cardiotoxicity in Breast Cancer PatientsUnited States
-
Zhejiang Cancer HospitalRecruitingCardiotoxicity Induced by Drug Therapy for Breast CancerChina
-
Rambam Health Care CampusUnknownMetastatic Breast Cancer | Cardiotoxicity. | Anti Her2 Therapy.Israel